On Pharma Trends and Big Company Innovation

Key takeaways

The pharmaceutical industry faces immense pressure to balance scientific advancements with business strategies, especially at scale.
Embracing a portfolio approach to R&D is essential for innovation and requires a commitment to rapid iteration and technological integration.
The complexity of clinical trials necessitates a move away from traditional models toward more adaptive strategies, emphasizing the role of technology.
Digital and data-driven approaches are increasingly relevant, offering new pathways for therapeutic development and patient engagement.
Fostering a company culture that encourages curiosity and open debate is critical for driving innovation and dealing with the challenges of modern medicine.

Summary

Balancing Science and Business in Pharma

Vas Narasimhan, CEO of Novartis, discusses the balance between the science of medicine development and the business aspects of innovation. The conversation highlights the complexity of decision-making in a massive pharmaceutical company, particularly concerning investing in new therapeutic areas compared to exiting those that are no longer viable. Narasimhan emphasizes the necessity of maintaining a diverse pipeline of medicines and being able to exit areas where growth is stagnating.

Innovation and R&D Strategies

The podcast dives deep into the strategies Novartis employs in their R&D processes. Narasimhan shares insights on moving from traditional drug development processes to increasingly complex cell and gene therapies. Key themes include how companies must shift focus from merely creating new therapeutic areas to building platforms that encourage rapid iteration and integration of various technologies such as AI and ML.

Clinical Trials and Regulatory Challenges

Narasinhan talks about the increasing complexity of clinical trials, emphasizing the need for rigorous criteria to ensure only transformative drugs move forward. The conversation includes the impact of evolving regulatory requirements and the necessity for companies to deploy technology efficiently to cut down trial costs and complications. Narasimhan also discusses the value of real-world evidence in confirming drug efficacy.

The Future of Healthcare and Digital Medicine

The discussion covers emerging trends in healthcare, particularly the promise of digital therapeutics. Innovations such as the use of RNA-based therapies are examined as they perturb traditional treatment modalities. Narasimhan talks about how Novartis is navigating the shift towards combining software and therapeutics, encapsulating the growing importance of data in health management.

Building a Culture for Innovation

The episode concludes with Narasimhan addressing the cultural shifts needed within large pharmaceutical companies to encourage innovation. He emphasizes the importance of creating an unbossed, collaborative environment where employees feel inspired and curious. This culture is crucial for navigating uncertainty and fostering creativity in a field that fundamentally deals with complex biological systems.

Show notes

How does the world’s largest producer of medicines in terms of volume balance the science and the business of innovation? How does an enterprise at such vast scale make decisions about what to build vs. buy, especially given the fast pace of science today? How does it balance attitudes between “not invented here” and “not invented yet”?

Vas Narasimhan, CEO of Novartis, sat down with a16z bio general partners Jorge Conde and Vijay Pande, and editor in chief Sonal Chokshi, during the JP Morgan Healthcare Conference around this time last year, to discuss the latest trends in therapeutics; go to market and why both big companies and bio startups need to get market value signals (not just approvals!) from payers earlier in the process; clinical trials, talent, leadership, and more in this rerun of the a16z Podcast.

image: Global Panorama/ Flickr

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.